Navigation Links
Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
Date:5/6/2008

- Conference Call Today at 5:00 p.m. Eastern Time -

SOUTH SAN FRANCISCO, Calif., May 6 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today reported on its corporate progress and financial results for the first quarter ended March 31, 2008.

"During the first quarter, we made significant progress in moving our clinical trials forward and generating data to demonstrate the potential of picoplatin as a new generation platinum therapy," said Jerry McMahon, Ph.D., chairman and CEO of Poniard. "Our pivotal Phase 3 SPEAR trial in small cell lung cancer continues to enroll patients. Today, we are pleased to announce the completion of patient enrollment in our Phase 2 trial in metastatic colorectal cancer. The results of our Phase 1 trials in prostate cancer and colorectal cancer were presented earlier this year. Encouraging bioavailability data has been presented from our ongoing Phase 1 trial of oral picoplatin. We secured commercial manufacture and supply of picoplatin drug substance. A new chief medical officer was appointed to expedite the clinical development of picoplatin through product approval. Our accomplishments this quarter are consistent with the development of picoplatin as a platform product addressing multiple indications, combinations and formulations."

First Quarter and Recent Highlights

Picoplatin and Development Pipeline

* Small Cell Lung Cancer: Presented final data from our Phase 2 trial

of picoplatin in small cell lung cancer (SCLC) at the International

Association for the Study of Lung Cancer and the European Society

for Medical Oncology's 1st European Lung Canc
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
5. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
6. Onyx Pharmaceuticals Reports 2008 First Quarter Results
7. SGX Pharmaceuticals Schedules Teleconference and Webcast to Discuss First Quarter 2008 Results and Provide Pipeline Update
8. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
9. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
10. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
11. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") today ... R-Pharm, a leading Russian pharmaceutical company, to develop and ... Russian Federation , Turkey ... is a novel antibiotic for the treatment of bacterial ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of strategic ... business, and media events in the United States ... associate Virginia Cox , JD, is returning to the firm,s ... Cox re-joins 3D after more than two years of service ...
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... May 15, 2012, JoVE ( Journal of Visualized ... United States government,s Defense Threat Reduction Agency (DTRA). ... University,s Dr. Chris Schafmeister and State University of New York ... The support of scientists conducting research for DTRA has significant ...
... Reportlinker.com announces that a new ... its catalogue: , Neuroendocrine Carcinoma ... Forecast to 2019 ... Therapeutics - Pipeline Assessment and Market ...
... BGI, one of the world,s largest genomics organizations, ... been successfully installed at its facility in Shenzhen, China. The ... sequencing technologies and enhance BGI,s long read sequencing capability. ... a Roche Company, features the unique combination of long reads, ...
Cached Biology Technology:JoVE partners with US government to publish cutting-edge defense research 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 2Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 3Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 4Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 5Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 6Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 7Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 8Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 9Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 10BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 2BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research 3
(Date:4/24/2014)... turtle is the largest river turtle in North America, ... almost a century. Now researchers from Florida and the ... one species but three. , Examining museum specimens ... in this ancient reptile. , Once heavily hunted for ... of Campbell,s Turtle Soup in the 1960s the ...
(Date:4/23/2014)... prevalence of asthma, allergies and other chronic inflammatory disorders ... in part to their reduced exposure to the microbes ... scientific paper. , The article, published in the journal ... living in urban centers who have less access to ... inflammation, a condition caused by immune system dysfunction. , ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Two new US turtle species described 2Two new US turtle species described 3Rural microbes could boost city dwellers' health 2Rural microbes could boost city dwellers' health 3On the defensive 2On the defensive 3
... A new study from researchers at Queen Mary, University of ... in self-managing their disease. People with diabetes have to ... their condition. This includes not only monitoring the level of ... restrictive diet but also social challenges such as negotiating relatives, ...
... N.Y. -- It turns out that the milk of human ... Research by psychologists at the University at Buffalo and ... part of the reason some people are kind and generous ... Poulin, PhD, assistant professor of psychology at UB, is the ...
... of the woodpecker,s resistance to head impact injury are ... group from the Key Laboratory for Biomechanics and Mechanobiology ... and Medical Engineering, Beihang University, and the School of ... out to study this problem. After 3 years of ...
Cached Biology News:Approach to diabetes self-management too narrow, study suggests 2Approach to diabetes self-management too narrow, study suggests 3Study finds peoples' niceness may reside in their genes 2Mechanical properties and microstructure of cranial and beak bones of the woodpecker and the lark 2
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
...
...
...
Biology Products: